VISIT VOLUME - Co said revenue growth was mainly driven by higher visit volumes from net clinician growth
CLINICIAN PRODUCTIVITY - Co cited improved clinician productivity as a contributor to revenue growth
OPERATING LEVERAGE - Adjusted EBITDA margin increased due to higher revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses
Outlook raised for 2026
LifeStance Health raises 2026 revenue guidance to $1.685 bln-$1.725 bln
Company expects Q3 revenue of $420 mln-$440 mln
LifeStance Health sees 2026 Adjusted EBITDA of $215 mln-$235 mln
Analyst coverage and valuation
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for LifeStance Health Group, Inc. is $13.00, about 25.4% above its August 5 closing price of $10.37
The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 77 three months ago
LFST•
